Kornimate/medical-research-clean huggingface dataset:
ticagrelor in fuwai hospital

Conditions: Acute Coronary Syndrome

Summary: this is a single-arm non-interventional cohort study. this study is to describe the contemporary use of ticagrelor in a "real-world" setting, to reflect its acceptance and patients' compliance, and to observe its one-year safety in patients with acute coronary syndrome in fuwai hospital.


Eligibility criteria:
inclusion criteria: 1. ≧18 years 2. established diagnosis of acute coronary syndrome 3. the use of ticagrelor in hospital 4. agree to join this clinical trial and sign informed consent exclusion criteria: 1. life-expectancy \<1 year 2. dialysis required

Keywords: ticagrelor acute coronary syndrome
response of liver to 12 weeks of resistance band training program in burned patients.

Conditions: Burns

Summary: serum concentrations of alanine transaminase (alt) and aspartate transaminase (ast) significantly increased immediately upon burn trauma and remained significantly elevated for about three years. resistance training has been shown to reduce the risk of insulin resistance, aminotransfer¬ase levels, dyslipidemia and impaired fasting glucose and can be beneficial for glucose-lipid metabolism.

1. measurement procedures: serum blood draws will be taken by certified technicians with the participant in a seated position. spectrophotometry is the measurable analysis technique using electromagnetic spectra. it deals with the ranges of wavelengths such as near ultraviolet, near-infrared and visible light. a device called a spectrophotometer is used to measure the absorbance or transmittance through a liquid sample. the spectrophotometer measures a specific wavelength and it is possible to choose any wavelength in the spectrophotometer register as the double beam sends a beam through a blank reference sample and one through the sample to be measured. normal values that will be used for patients are 0-45 iu/l for alanine transaminase (alt) and 0-35 iu/l for aspartate transaminase(ast) measurements will be taken before the treatment (pre-treatment) and after 12 weeks (post-treatment). 2. therapeutic procedures: resistance band for resistance training: resistance training will be performed for 12 weeks for 3 sessions/week on non-consecutive days. the program will consist of six exercises: triceps press, biceps curl, lat pull-down, leg press, leg extension and sit-ups using a resistance band. each session will last approximately 45 minutes and consist of a 5-minute warm-up with stretching followed by resistance training that will be done as a cir¬cuit, ending with a 5-minute cooldown. the 1 repetition maximum (1rm) is measured at baseline and following the intervention. initially, participants will do two circuits using 50% of their 1rm and repeat them 10 times for the first 3 weeks, progressing to two circuits, using 60% of their 1rm and repeating 10 times for the second 3 weeks. during the third 3 weeks, participants will do three circuits using 60% of their 1rm and repeat 10 times. in the last 3 weeks, patients will do three circuits using 70% of their 1rm and repeat 10 times. a 90-second rest will be allowed between sets of exercises.

Eligibility criteria:
inclusion criteria: the subject selection will be according to the following criteria: * age range between 20-45 years. * male and female patients will participate in the study. * all patients have burn with bbsa about 30% to 50%. * all patients enrolled to the study will have their informed consent. exclusion criteria: * the potential participants will be excluded if they meet one of the following criteria: * cardiac diseases. * burn of sole of foot. * exposed hand or foot tendons. * upper or lower limb amputation. * history of liver diseases. * body mass index (bmi=kg/cm2)\<30%.
effects of prescription omega-3 on ldl-c in primary hypercholesterolemia

Conditions: Primary Hypercholesterolemia

Summary: the objectives of this study are to assess the effects of 4 g/d p-om3, compared with placebo, on ldl-c and other aspects of the fasting lipid profile in subjects with primary hypercholesterolemia.

this trial will utilize a randomized, double-blind, two-period crossover design. at visit 2 (week 0), subjects meeting all entry criteria will be randomized to one of two treatment sequences: placebo or p-om3 for the first 6 week phase followed by the study product they did not receive during the first phase (p-om3 or placebo) for the second 6 weeks.

Eligibility criteria:
inclusion criteria: * men and women, ages 18-79 inclusive * fasting, untreated low-density lipoprotein cholesterol (ldl-c)level in the borderline high to very high range * fasting, untreated triglyceride (tg)level in the normal range * provide written informed consent and authorization for protected health information exclusion criteria: * chd or chd risk equivalent * pregnancy * use of lipid altering medications which cannot be stopped * body mass index over 45 kg per square meter * allergy or sensitivity to omega-3 fatty acids * certain muscle, liver, kidney, lung or gastrointestinal conditions * poorly controlled hypertension * certain medications * active cancers treated within prior 2 years (except non-melanoma skin cancer)

Keywords: cholesterol hypercholesterolemia omega 3
"preventing cardiovascular ischemic events and arresting their consequences in type 2 diabetic population

Conditions: Type2 Diabetes Mellitus; Microangiopathy; Non Alcoholic Fatty Liver Disease; Coronary Artery Disease; Cerebrovascular Disease; Acute Coronary Syndrome/ Myocardial Infarction; Ictus

Summary: current methods based on traditional cardiovascular risk factors are not clinically useful for identifying type 2 diabetes patients at risk of developing acute cardiovascular ischemic events (ie.myocardial infarction or stroke). in addition, cardiovascular ischemic events in type 2 diabetes population have worse prognosis than in general population. in fact, there is sufficient experimental evidence indicating that diabetes exaggerates the deleterious effects of ischemic events and worsens their outcome. a prolonged sub-clinical phase exists before a cardiovascular event occurs in type 2 diabetes patients. therefore, new strategies aimed at identifying those patients with this subclinical cardiovascular diabetes and, consequently, more prone to develop cardiovascular events is a challenge to be met.

objectives 1) to examine whether the extension and degree of microangiopathy is an independent risk factor for silent myocardial and brain ischemia. 2) to evaluate whether the degree and extension of microangiopathy is a predictor of cv events and poor outcome. 3) to evaluate whether a new score based on the extension and the degree of microangiopathy will permit us to improve the current methods used to identify patients at risk of cvd and its outcomes. 4) to determine whether the presence and the degree of nafld is an independent cardiovascular disease risk factor and represent and extra-value to the score based on the extension and the degree of microangiopathy. secondary objectives: 1) to examine the usefulness of selected serum biomarkers in identifying diabetic patients at risk of cardiovascular disease 2) to evaluate whether these selected biomarkers are related to the degree and extension of microangiopathy and the outcome of cardiovascular events. 3) to better define the meaning of microalbuminuria in type 2 diabetic population (glomerular involvement vs. index of generalized endothelial dysfunction)

Eligibility criteria:
inclusion criteria: * a) age from 50-79 years; b) history of type 2diabetes of at least one year. diabetes will be defined following the american diabetic association criteria: fasting glucose level of at least 126 mg/dl \[7.0 mmol/l\] in two separate analyses, a non-fasting glucose level of at least 200 mg/dl \[11.1 mmol/l\] or a self-reported history of physician-diagnosed diabetes or treatment for diabetes exclusion criteria: * a) past medical history of cardiovascular event; b) type 1 diabetes; c) contraindication for pet-ct or mri d) other concomitant disease associated with a short life expectancy
emotional state among patients with neurological disorders

Conditions: Emotional Stress; Emotional Depression; Anxiety; Neurologic Disorder

Summary: the purpose of the study was to examine the emotional state of the patients with neurological disorders. the evaluation was conducted with dass-21 scale over 40 patients.

the depression, anxiety and stress scale - 21 items (dass-21) is a set of three self-report scales designed to measure the emotional states of depression, anxiety and stress.the dass-21 should not be used to replace a face to face clinical interview.

Eligibility criteria:
inclusion criteria: * patients with neurological disorders exclusion criteria: * not given concent * incomplete questionaire answers

Keywords: stress anxiety depression neurologic disorders
atrial and brain natriuretic peptide secretion after percutaneous closure of the left atrial appendage

Conditions: Atrial Fibrillation; Stroke Prevention; Left Atrial Appendage

Summary: to date there are no data suggesting substantial effects of hormonal interaction after percutaneous closure of the left atrial appendage (laa). our hypothesis is that by excluding the laa from blood flow physiologic stimuli for anp and bnp produce may be impaired and consecutive release of the hormones may be reduced. here, we present our experience of anp and bnp secretion in the early postprocedural period after transcatheter closure of the laa.


Eligibility criteria:
inclusion criteria: * non-valvular atrial fibrillation * increased risk for thromboembolic complications (a minimum chads2score of at least 2) exclusion criteria: * valvular-atrial fibrillation * low risk for thromboembolic complications chads-2-score \< 2
improvement of hyperglycemia/diabetes in patients to improve safety

Conditions: Diabetes Mellitus, Type 2

Summary: the goal of this project is to bring together staff and clinicians from northwestern university/northwestern medical group/northwestern memorial hospital as well as patients and caregivers to assess and redesign the identification and management of hyperglycemia and diabetes during and in transitions of care. there will be 3 different groups for the study: a group of providers \[group 1\], a group of patients/caregivers and laypersons \[group 2\], and a stakeholder group \[group 3\]. participants will be asked to provide input on potential interventions for a future clinical trial.


Eligibility criteria:
inclusion criteria: * provider group: multidisciplinary clinical team (including but not limited to inpatient endocrine nurse practitioners, nurse coordinators, diabetes educators, outpatient nurses, attending physicians, and pharmacists) * patient, caregiver and layperson group: patients must have had hyperglycemia or diabetes at northwestern memorial hospital in the last 5 years. * stakeholder group: involved in the specific care delivery of diabetes exclusion criteria: * provider group: none * patient, caregiver, and layperson group: patients will be excluded if they did not have diabetes or had hyperglycemia. * stakeholder group: none
safety and performance of the covidien eea hemorrhoid and prolapse stapling set in a hemorrhoidopexy procedure

Conditions: Hemorrhoid

Summary: trial objectives the primary objectives of this clinical trial are to estimate the covidien eea™ hemorrhoid and prolapse stapling set: overall performance defined by the successful creation of a normal staple line safety as measured by the 30 day incidence of adverse events.


Eligibility criteria:
inclusion criteria: * able to understand and sign informed consent form * the participant must be 18-80 years of age. * the participant has (symptomatic) grade 2-4 hemorrhoids and is eligible for stapled hemorrhoidopexy. exclusion criteria: * the procedure is needed as revision hemorrhoid surgery. * the participant is pregnant. * the participant has an active or a history of infection requiring antibiotics at the intended operative site within thirty (30) days prior to the planned surgery date. * the participant is unable or unwilling to comply with the study requirements, follow-up schedule. * the participant has a history of drug or alcohol abuse. * the participant has a history of venous thrombosis or pulmonary embolism. * the participant has a history of coagulopathy. * the participant is taking aspirin, anti-coagulation and/or anti platelet therapies (e.g.: warfarin, levonox) within the last 7 days prior to the planned surgery date * the participant has a history of fecal incontinence. * the participant has co-morbidities which, in the opinion of the investigator, will not be appropriate for the study.

Keywords: hemorrhoids hemorrhoid grade ii, iii, iv
prevention of atrial arrhythmia in patients without atrioventricular (av) conduction disease

Conditions: Sinus Node Dysfunction; Brady Tachy Syndrome

Summary: this clinical investigation is a prospective, single-blinded, randomized trial. the primary objective concerns the safety and effectiveness of the aaisafer mode with the preventive algorithms.

in this study, patients are randomized to ddd mode, aaisafer mode, or aaisafer mode plus atrial arrhythmia preventive algorithms. the atrial arrhythmia (aa) burden serves as the primary measure of effectiveness.

Eligibility criteria:
inclusion criteria: * a pacemaker indication for sinus node dysfunction and/or brady-tachy syndrome or already implanted for less than three months for the mentioned reasons and supplied with a symphony 2550 dr at time of inclusion and * a pr interval \<250ms and * documented atrial arrhythmia in the past year * medication for anti-arrhythmic must be stable for at least one month (2 months for amiodarone) prior to enrollment * patients must have less than two known cardioversions within the last year * patient has signed a consent form after having received the appropriate information exclusion criteria: * need a replacement pacemaker device * have an unknown pr interval * known av block ≥ 250 ms pr interval * minor and/or pregnant woman * patients enrolled in other clinical trials * patients with sustained ventricular arrhythmia * patients with severe coronary artery disease (at the discretion of the investigator) * patients with advanced cardiomyopathy (at the discretion of the investigator) * patients who have sustained a myocardial infarction or undergone cardiac surgery within the past 30 days * patients with unstable angina pectoris * patients whose life expectancy is less than 1 year * patients who are unlikely to return for required follow-up visits * patients who present with permanent atrial arrhythmia or those who usually require cardioversion to terminate such arrhythmia and/or * patients whose physician plans to add or change medical treatment because of aa episodes during the follow-up period. * patient unable to understand the purpose of the study or refusing to cooperate
effects of allergen inhalation on adenosine receptor expression in sputum and peripheral blood

Conditions: Asthma; Healthy

Summary: the purpose of this study is to determine whether asthmatics have different adenosine receptor expression profiles than healthy controls. we hypothesize that asthmatics will have increased adenosine receptor expression versus control subjects. we also want to study the effects of allergen inhalation on adenosine receptor expression in asthmatics. we believe that adenosine receptor expression will be upregulated after allergen inhalation. both hypotheses are being tested in sputum and peripheral blood.


Eligibility criteria:
asthmatic subjects - inclusion criteria: * clinical diagnosis of asthma * steroid naive or subjects not using their inhaled steroids for the last 4 weeks, short-acting beta-agonist for rescue medication * fev1 \> 70% of predicted * positive skin prick test for house dust mite, cat or grass pollen * pc20 methacholine or histamine \< 8 mg/ml asthmatic subjects - exclusion criteria: * use of systemic steroids in the previous 6 weeks * asthma exacerbations in the previous 6 weeks * current or ex-smokers with ≥ 10 pack-years (≥ 2 pipe pack-years), ex smokers who stopped less than 1 year ago healthy subjects - inclusion criteria: * no airway complaints * fev1 \> 90% of predicted * negative skin prick test * pc20 methacholine or histamine \> 8 mg/ml healthy subjects - exclusion criteria: * use of steroids in the previous 6 weeks * current or ex-smokers with ≥ 10 pack-years (≥ 2 pipe pack-years), ex smokers who stopped less than 1 year ago

Keywords: adenosine receptors asthma sputum peripheral blood healthy
evaluation of two silicone hydrogel lenses over a one month period

Conditions: Myopia

Summary: the purpose of this trial is to compare two different contact lenses during 4 weeks of wear.


Eligibility criteria:
inclusion criteria: * current soft contact lens wearer who wear their habitual lenses for no less than 10 hours a day, 5 days a week * have a need for correction in both eyes and be correctable to at least 20/40 distance vision in each eye while wearing trial lenses * replace lenses on a weekly or longer schedule * other protocol inclusion/exclusion criteria may apply exclusion criteria: * requires concurrent ocular medication * eye injury or surgery within twelve weeks immediately prior to enrollment * evidence of systemic or ocular abnormality, infection, or disease likely to affect successful wear of contact lenses or use of their accessory solutions * current soft toric lens wearers * those who dispose of their soft lenses on a daily basis * current night \& day® or biofinity® lens wearers * other protocol-defined inclusion/exclusion criteria may apply
prepared meals to prime and perpetuate reduced dietary sodium intake in hemodialysis

Conditions: Hypertension in Dialysis Patients; Fluid Overload in Dialysis Patients

Summary: this is a randomized clinical trial in which maintenance hemodialysis patients will be provided with salt restricted 'dialysis friendly' meals and compared to a control arm receiving usual care.

patients randomized to the intervention arm will receive 2 months of meals plus dietary counseling. counseling will continue for an additional 3 months while the control arm will have 5 months of usual care followed by 2 months of meal provision. effects on interdialytic weight gain, achievement of target dry weight, intradialytic hypotension episodes, blood pressure, and a volume assessment using lung u/s to assess lung water will be measured. salt sensitivity will be tested throughout the study. self reported questionnaires about the burden of adhering to the low salt diet and the level of adherence with it will be completed at baseline and throughout the study. the investigator hypothesizes that the prepared meals with prime patients behavior and may alter salt taste perception and that these effects will be sustained after the prepared meals have stopped.

Eligibility criteria:
inclusion criteria: 1. age \>18 2. treated with outpatient hemodialysis for \>60 days 3. mean idwg over the past 30 days \>2 kg 4. speaks and understands english or chinese 5. patient has a freezer at home with space to store at least 7 prepared meals 6. cognitively intact (able to provide informed consent and answer questionnaires) exclusion criteria: -
dose response of whey and soy protein ingestion with and without resistance exercise in elderly men

Conditions: Sarcopenia

Summary: when we age, we lose muscle. it is not exactly clear why this happens, but we do know that this muscle loss can increase health risks and lead to health problems. lifting weights (i.e. performing resistance exercise) and proper nutrition, in particular eating enough high quality protein, can help slow the loss of muscle mass or potentially even reverse it. protein and resistance exercise are thought to do this by stimulating your muscle to make more proteins and/or potentially by slowing down the rate at which your body breaks proteins down. whey protein is a high quality protein isolated from milk and is known to stimulate new protein synthesis for all proteins in your body. however, to date, the effect that whey protein has on muscle protein synthesis, particularly in the elderly has yet to be determined. thus the purposes of this study are: 1) to determine if whey is an effective source of protein that will stimulate muscle protein synthesis in the elderly, similar to what we have previously seen in young persons; 2) to determine the smallest amount of whey protein to consume to maximally stimulate your muscle to make new proteins; 3) to see if performing resistance exercise will augment the increase in new muscle protein synthesis with whey consumption; and 4) to try and found out if whey is more effective than soy protein in stimulating new muscle protein synthesis and suppressing muscle protein breakdown in the elderly, similar to what we have previously seen in young persons


Eligibility criteria:
inclusion criteria: * male * aged 60 to 80 years old * non-smoker * generally healthy and can tolerate the resistance exercise and protein drink exclusion criteria: * allergies to whey, casein or soy * health problems such as: heart disease, rheumatoid arthritis of the knee joint, diabetes, poor lung function, uncontrolled hypertension, or any health conditions that might put participants at risks for this study * failed clearance for exercise participation by their medical doctor * failed an exercise stress test * taking metformin and/or other medications for the control of blood glucose even though one might not be classified as diabetic * taking prescribed blood thinners such as warfarin and heparin but excluding aspirin * taking medications for lung and kidney conditions but excluding medication for asthma that is under control

Keywords: sarcopenia muscle protein muscle protein synthesis muscle protein breakdown whey soy casein dose response resistance exercise unilateral knee extension whole body protein